MarketPulse

biotech stock

4 articles
The Motley FoolThe Motley Fool··Eric Volkman

Nektar Therapeutics Surges 18% on Positive Alopecia Drug Trial Results

Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.
NKTRclinical trial resultsbiotech stock
The Motley FoolThe Motley Fool··Robert Izquierdo

MoonLake CEO Sells $2.8M in Stock as Biotech Faces Clinical Setbacks

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold $2.8M in shares, reducing holdings 4.9%. Stock down 47% year-over-year amid disappointing trial results.
MLTXhigh-risk investmentinsider selling
The Motley FoolThe Motley Fool··David Jagielski, Cpa

CRISPR Therapeutics Stock Slumps 9% Despite Casgevy Approval and Strong Cash Position

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.
VRTXCRSPgene editingCasgevy
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges on Positive Phase 3 Psilocybin Trial Results

Compass Pathways stock surged 44% after positive Phase 3 trial results for psilocybin depression therapy. FDA application expected by end of 2024.
CMPSFDA approvaltreatment-resistant depression